Will bacteria enable personalized medicine?

Bacteria are no longer the enemy. Scientists and entrepreneurs have entered a race to develop tools and datasets that uncover the role microbes play in human health.

The human body contains a complex environment of bacteria that live on the skin, and in the mouth and gut — the microbiome. Genetic information in the microbiome outnumbers genetic information in human cells by 40:1

Advances in DNA sequencing and big data allow us to analyze bacteria like never before. Companies that focus on the microbiome could transform multi-billion dollar concerns like weight loss ($60B), probiotics ($30B), cosmetics, dental health, and even chronic diseases like diabetes.Will microbiome analysis change modern medicine? How are entrepreneurs involved? Is the money in sequencing, analytics, or drug development?

Join us on Tuesday, February 17th as our panelists and demo companies seek to answer these questions.

Moderator:
Mark Bünger, Sr. Research Director, Lux Research

Panelists:
Colleen Cutcliffe, Ph.D., Co-founder & CEO, Whole Biome
Karim Dabbagh, Ph.D., Chief Scientific Officer, Second Genome
Jackie Papkoff, Ph.D., Vice President, Johnson & Johnson Innovation
Douglas Crawford, Ph.D., Managing Director, Mission Bay Capital, Associate Director, QB3

Demo Companies:
AOBiome, Nubiome, Stanford Relman Lab, PacBio